Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients

Daria Trabattoni, Sergio Lo Caputo, Mara Biasin, Elena Seminari, Massimo Di Pietro, Giovanni Ravasi, Francesco Mazzotta, Renato Maserati, Maria Clerici

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Analysis of the virologic and immunomodulatory effects of an association of efavirenz (EFV), nelfinavir (NFV), and stavudine (d4T) was performed in 18 human immunodeficiency virus (HIV)-infected and highly active antiretroviral therapy (HAART)-experienced patients who failed multiple therapeutic protocols. Patients (+ cells/μl; >10,000 HIV copies/ml) were nonnucleoside reverse transcriptase inhibitor (NNRTI)-naive and were treated for 10 months with EFV (600 mg/day) in association with NFV (750 mg three times daily) and d4T (30 or 40 mg twice daily). Measurement of HIV peptide- and mitogen-stimulated production of interleukin-2 (IL-2), gamma interferon (IFN-γ), IL-4, and IL-10 as well as quantitation of mRNA for the same cytokines in unstimulated peripheral blood mononuclear cells were performed at baseline and 2 weeks (tl), 2 months (t2), and 10 months (t3) into therapy. The results showed that HIV-specific (but not mitogen-stimulated) IL-2 and IFN-γ production was augmented and IL-10 production was reduced in patients who received EFV, NFV, and d4T. Therapy was also associated with a reduction in HIV RNA in plasma and an increase in CD4+ cell count. These changes occurred in the first year of therapy (t2 and t3) and were confirmed by quantitation of cytokine-specific mRNA. Therapy with EFV, NFV, and d4T increases HIV-specific type 1 cytokine production as well as CD4 counts and reduces plasma viremia. This therapeutic regimen may be considered for use in cases of advanced HIV infection.

Original languageEnglish
Pages (from-to)1114-1118
Number of pages5
JournalClinical and Diagnostic Laboratory Immunology
Volume9
Issue number5
DOIs
Publication statusPublished - Sep 2002

Fingerprint

efavirenz
Nelfinavir
Stavudine
Viruses
Modulation
HIV
Pharmaceutical Preparations
CD4 Lymphocyte Count
Cytokines
Mitogens
Interleukin-10
Interleukin-2
Therapeutics
Association reactions
Messenger RNA
Reverse Transcriptase Inhibitors
Viremia
Plasmas
Highly Active Antiretroviral Therapy
Virus Diseases

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. / Trabattoni, Daria; Lo Caputo, Sergio; Biasin, Mara; Seminari, Elena; Di Pietro, Massimo; Ravasi, Giovanni; Mazzotta, Francesco; Maserati, Renato; Clerici, Maria.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 9, No. 5, 09.2002, p. 1114-1118.

Research output: Contribution to journalArticle

@article{3bb580810bd34e62bd84abfc5cb00fa0,
title = "Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients",
abstract = "Analysis of the virologic and immunomodulatory effects of an association of efavirenz (EFV), nelfinavir (NFV), and stavudine (d4T) was performed in 18 human immunodeficiency virus (HIV)-infected and highly active antiretroviral therapy (HAART)-experienced patients who failed multiple therapeutic protocols. Patients (+ cells/μl; >10,000 HIV copies/ml) were nonnucleoside reverse transcriptase inhibitor (NNRTI)-naive and were treated for 10 months with EFV (600 mg/day) in association with NFV (750 mg three times daily) and d4T (30 or 40 mg twice daily). Measurement of HIV peptide- and mitogen-stimulated production of interleukin-2 (IL-2), gamma interferon (IFN-γ), IL-4, and IL-10 as well as quantitation of mRNA for the same cytokines in unstimulated peripheral blood mononuclear cells were performed at baseline and 2 weeks (tl), 2 months (t2), and 10 months (t3) into therapy. The results showed that HIV-specific (but not mitogen-stimulated) IL-2 and IFN-γ production was augmented and IL-10 production was reduced in patients who received EFV, NFV, and d4T. Therapy was also associated with a reduction in HIV RNA in plasma and an increase in CD4+ cell count. These changes occurred in the first year of therapy (t2 and t3) and were confirmed by quantitation of cytokine-specific mRNA. Therapy with EFV, NFV, and d4T increases HIV-specific type 1 cytokine production as well as CD4 counts and reduces plasma viremia. This therapeutic regimen may be considered for use in cases of advanced HIV infection.",
author = "Daria Trabattoni and {Lo Caputo}, Sergio and Mara Biasin and Elena Seminari and {Di Pietro}, Massimo and Giovanni Ravasi and Francesco Mazzotta and Renato Maserati and Maria Clerici",
year = "2002",
month = "9",
doi = "10.1128/CDLI.9.5.1114-1118.2002",
language = "English",
volume = "9",
pages = "1114--1118",
journal = "Clinical and Diagnostic Laboratory Immunology",
issn = "1071-412X",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients

AU - Trabattoni, Daria

AU - Lo Caputo, Sergio

AU - Biasin, Mara

AU - Seminari, Elena

AU - Di Pietro, Massimo

AU - Ravasi, Giovanni

AU - Mazzotta, Francesco

AU - Maserati, Renato

AU - Clerici, Maria

PY - 2002/9

Y1 - 2002/9

N2 - Analysis of the virologic and immunomodulatory effects of an association of efavirenz (EFV), nelfinavir (NFV), and stavudine (d4T) was performed in 18 human immunodeficiency virus (HIV)-infected and highly active antiretroviral therapy (HAART)-experienced patients who failed multiple therapeutic protocols. Patients (+ cells/μl; >10,000 HIV copies/ml) were nonnucleoside reverse transcriptase inhibitor (NNRTI)-naive and were treated for 10 months with EFV (600 mg/day) in association with NFV (750 mg three times daily) and d4T (30 or 40 mg twice daily). Measurement of HIV peptide- and mitogen-stimulated production of interleukin-2 (IL-2), gamma interferon (IFN-γ), IL-4, and IL-10 as well as quantitation of mRNA for the same cytokines in unstimulated peripheral blood mononuclear cells were performed at baseline and 2 weeks (tl), 2 months (t2), and 10 months (t3) into therapy. The results showed that HIV-specific (but not mitogen-stimulated) IL-2 and IFN-γ production was augmented and IL-10 production was reduced in patients who received EFV, NFV, and d4T. Therapy was also associated with a reduction in HIV RNA in plasma and an increase in CD4+ cell count. These changes occurred in the first year of therapy (t2 and t3) and were confirmed by quantitation of cytokine-specific mRNA. Therapy with EFV, NFV, and d4T increases HIV-specific type 1 cytokine production as well as CD4 counts and reduces plasma viremia. This therapeutic regimen may be considered for use in cases of advanced HIV infection.

AB - Analysis of the virologic and immunomodulatory effects of an association of efavirenz (EFV), nelfinavir (NFV), and stavudine (d4T) was performed in 18 human immunodeficiency virus (HIV)-infected and highly active antiretroviral therapy (HAART)-experienced patients who failed multiple therapeutic protocols. Patients (+ cells/μl; >10,000 HIV copies/ml) were nonnucleoside reverse transcriptase inhibitor (NNRTI)-naive and were treated for 10 months with EFV (600 mg/day) in association with NFV (750 mg three times daily) and d4T (30 or 40 mg twice daily). Measurement of HIV peptide- and mitogen-stimulated production of interleukin-2 (IL-2), gamma interferon (IFN-γ), IL-4, and IL-10 as well as quantitation of mRNA for the same cytokines in unstimulated peripheral blood mononuclear cells were performed at baseline and 2 weeks (tl), 2 months (t2), and 10 months (t3) into therapy. The results showed that HIV-specific (but not mitogen-stimulated) IL-2 and IFN-γ production was augmented and IL-10 production was reduced in patients who received EFV, NFV, and d4T. Therapy was also associated with a reduction in HIV RNA in plasma and an increase in CD4+ cell count. These changes occurred in the first year of therapy (t2 and t3) and were confirmed by quantitation of cytokine-specific mRNA. Therapy with EFV, NFV, and d4T increases HIV-specific type 1 cytokine production as well as CD4 counts and reduces plasma viremia. This therapeutic regimen may be considered for use in cases of advanced HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0036735336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036735336&partnerID=8YFLogxK

U2 - 10.1128/CDLI.9.5.1114-1118.2002

DO - 10.1128/CDLI.9.5.1114-1118.2002

M3 - Article

C2 - 12204968

AN - SCOPUS:0036735336

VL - 9

SP - 1114

EP - 1118

JO - Clinical and Diagnostic Laboratory Immunology

JF - Clinical and Diagnostic Laboratory Immunology

SN - 1071-412X

IS - 5

ER -